Dr. Galal on CAR T-Cell Therapy in Relapsed/Refractory Lymphomas

Video

Ahmed Galal, MD, instructor, Department of Medicine, Duke Cancer Institute, discusses the use of CAR T-cell therapy in patients with relapsed/refractory lymphomas.

Ahmed Galal, MD, instructor, Department of Medicine, Duke Cancer Institute, discusses the use of CAR T-cell therapy in patients with relapsed/refractory lymphomas.

CAR T-cell therapy is currently FDA-approved for patients with aggressive lymphoma subtypes, such as diffuse large B-cell lymphoma, primary mediastinal lymphoma, and other high-grade lymphomas. These patients are typically eligible for CAR T cell-therapy after having developed resistance to prior 2 lines of treatment. Galal says that approximately 40% of patients will progress on frontline R-CHOP (rituximab [Rituxan], cyclophosphamide, doxorubicin, vincristine, and prednisone) or R-EPOCH (rituximab, etoposide phosphate, prednisone, vincristine sulfate, cyclophosphamide, and doxorubicin hydrochloride), and only 30% of those patients will benefit from an autologous stem cell transplant. Thus, CAR T cells can make a difference in a fairly large population of patients that had once represented an unmet need.

This approach has provided new hope for these patients in the third-line setting, he concludes.

Related Videos
Dilsher Dhoot, MD, on a Promising Start With Diabetic Retinopathy Gene Therapy RGX-314
J. Andrew Livingston, MD, on Forging Forward With Novel Sarcoma Trials
Shankar Musunuri, PhD, on Gene Modifier Therapy vs Gene Replacement Therapy for IRDs
Pat Furlong, BSN, RN, on the State of Gene Therapy in Muscular Dystrophy
Michael Kelly, PhD, on Continuing Progress With Gene Therapy in Muscular Dystrophy
Thomas McCauley, PhD, on Potential Advantages of Epigenetic Therapy Over Small Molecule, Gene Therapy
© 2023 MJH Life Sciences

All rights reserved.